Publications by Lambert Charles François Potin

Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients

Davide Demurtas, Melody Swartz, Romain Hamelin, Lambert Charles François Potin, Patricia Corthésy Henrioud, Natacha Anne-Sophie Bordry, Maria Anna Sofia Broggi, Léa Maillat, Alexandre Harari

Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph sh ...

ROCKEFELLER UNIV PRESS2019

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Jeffrey Alan Hubbell, Melody Swartz, Seung Tae Lee, Lambert Charles François Potin, Jun Ishihara, Kazuto Fukunaga, Michal Mateusz Raczy

Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we addressed ...

AMER ASSOC ADVANCEMENT SCIENCE2019

Recruitment of CD103(+) dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy

Jeffrey Alan Hubbell, Lambert Charles François Potin, Melody Swartz, Jun Ishihara

Although a clinical breakthrough for cancer treatment, it remains that a minority of patients respond to checkpoint inhibitor (CPI) immunotherapy. The composition of tumor-infiltrating immune cells has been identified as a key factor influencing CPI therap ...

2019

Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity

Jeffrey Alan Hubbell, Melody Swartz, Lambert Charles François Potin, Martina Damo, Jun Ishihara, Kazuto Fukunaga

CD40 is an immune costimulatory receptor expressed by antigen-presenting cells. Agonistic anti-CD40 antibodies have demonstrated considerable antitumor effects yet can also elicit serious treatment-related adverse events, such as liver toxicity, including ...

AMER ASSOC CANCER RESEARCH2018

New roles of the lymphatic endothelium in modulating adaptive immunity: implications for immune tolerance and cancer immunotherapy

Lambert Charles François Potin

Lymphatic vessels have traditionally been considered as passive conduits for interstitial fluid drainage and for immune cell trafficking to lymph nodes. In the last two decades, many studies have challenged this classical dogma: lymphatic endothelial cells ...

EPFL2018

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

Jeffrey Alan Hubbell, Melody Swartz, Hans Mattias Larsson, Lambert Charles François Potin, Gabriele Galliverti, Jun Ishihara, Kazuto Fukunaga

Immune checkpoint blockade exhibits considerable antitumor activity, but previous studies have reported instances of severe treatment-related adverse events. We sought to explore local immune checkpoint blockade, with an antibody (Ab) form that would be re ...

Amer Assoc Advancement Science2017

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

Melody Swartz, Douglas Hanahan, Olivier Michielin, Krisztian Homicsko, Marcela Rincón-Restrepo, Christopher Claude Giuseppe Tremblay, Amanda Waite Lund, Laura Jeanbart, Lambert Charles François Potin, Manuel Andreas Fankhauser

In melanoma, vascular endothelial growth factor-C (VEGF-C) expression and consequent lymphangiogenesis correlate with metastasis and poor prognosis. VEGF-C also promotes tumor immunosuppression, suggesting that lymphangiogenesis inhibitors may be clinicall ...

Amer Assoc Advancement Science2017

Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges

Melody Swartz, Lambert Charles François Potin

Lymphatic vessels are the primary route of communication from peripheral tissues to the immune system; as such, they represent an important component of local immunity. In addition to their transport functions, new immunomodulatory roles for lymphatic vess ...

Elsevier Science Bv2017

Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance

Melody Swartz, Lambert Charles François Potin

Dendritic cells (DCs), and more recently lymph node stromal cells (LNSCs), have been described to tolerize self-reactive CD8(+) T cells in LNs. Although LNSCs express MHCII, it is unknown whether they can also impact CD4(+) T cell functions. We show that t ...

Rockefeller Univ Press2014